We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+2.01%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.42B
AUM Growth
+$183M
Cap. Flow
+$291M
Cap. Flow %
20.46%
Top 10 Hldgs %
37.91%
Holding
267
New
57
Increased
30
Reduced
117
Closed
58

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$19.5M
2
BCYC
Bicycle Therapeutics
BCYC
+$18.4M
3
INBX
Inhibrx, Inc. Common Stock
INBX
+$8.57M
4
IMTX icon
Immatics
IMTX
+$8.37M
5
AYLA
Ayala Pharmaceuticals, Inc. Common Stock
AYLA
+$6.47M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$30.7M
2
ALEC icon
Alector
ALEC
+$14.1M
3
CRSP icon
CRISPR Therapeutics
CRSP
+$11.5M
4
ANVS icon
Annovis Bio
ANVS
+$8.86M
5
CGEM icon
Cullinan Oncology
CGEM
+$7.61M

Sector Composition

Rank Sector Weight
1 Healthcare 30.01%
2 Consumer Staples 0.24%
3 Technology 0.17%
4 Financials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INCY icon
51
CALL
Incyte
INCY
$24.9B
$6.79M 0.48%
98,700
-101,300
-51% -$7.7M
IGMS
52
CALL
DELISTED
IGM Biosciences
IGMS
$6.58M 0.46%
+100,000
New +$7.65M
ELAN icon
53
CALL
Elanco Animal Health
ELAN
$13.2B
$6.38M 0.45%
+200,000
New +$6.71M
ZNTL icon
54
Zentalis Pharmaceuticals
ZNTL
$350M
$6.15M 0.43%
+92,344
New +$5.33M
AYLA
55
DELISTED
Ayala Pharmaceuticals, Inc. Common Stock
AYLA
$6.11M 0.43%
+538,939
New +$6.47M
AZN icon
56
CALL
AstraZeneca
AZN
$266B
$6.01M 0.42%
+50,000
New +$5.82M
SCPH
57
DELISTED
scPharmaceuticals
SCPH
$5.99M 0.42%
901,362
-193,662
-18% -$1.16M
FATE icon
58
PUT
Fate Therapeutics
FATE
$293M
$5.93M 0.42%
100,000
– –
BCAB icon
59
BioAtla
BCAB
$5.61M
$5.78M 0.41%
3,928
+2,525
+180% +$4.92M
XENE icon
60
Xenon Pharmaceuticals
XENE
$6.2B
$5.77M 0.41%
377,438
-263,168
-41% -$4.57M
BCYC
61
CALL
Bicycle Therapeutics
BCYC
$280M
$5.41M 0.38%
+130,000
New +$4.55M
ODT
62
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$5.36M 0.38%
1,840,631
-145,781
-7% -$485K
ALDX icon
63
CALL
Aldeyra Therapeutics
ALDX
$96.5M
$5.27M 0.37%
+600,000
New +$5.51M
ATYR
64
aTyr Pharma
ATYR
$47.1M
$5.11M 0.36%
562,246
+262,246
+87% +$1.57M
CLVS
65
DELISTED
Clovis Oncology, Inc.
CLVS
$4.96M 0.35%
1,112,669
-16,804
-1% -$80.9K
CMRX
66
DELISTED
Chimerix, Inc.
CMRX
$4.96M 0.35%
801,308
-774,608
-49% -$5.33M
OCUL icon
67
CALL
Ocular Therapeutix
OCUL
$1.85B
$4.93M 0.35%
493,200
-206,800
-30% -$2.32M
WVE icon
68
Wave Life Sciences
WVE
$1.13B
$4.87M 0.34%
+993,481
New +$6.02M
IOVA icon
69
PUT
Iovance Biotherapeutics
IOVA
$2.09B
$4.83M 0.34%
196,000
-4,000
-2% -$94.3K
ACAD icon
70
Acadia Pharmaceuticals
ACAD
$4.55B
$4.68M 0.33%
281,765
+71,899
+34% +$1.39M
BLU
71
DELISTED
BELLUS Health Inc.
BLU
$4.57M 0.32%
744,616
-265,929
-26% -$1.01M
LKFT
72
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.81B
$4.54M 0.32%
86,865
-113,135
-57% -$6.72M
AUPH icon
73
CALL
Aurinia Pharmaceuticals
AUPH
$1.93B
$4.43M 0.31%
+200,000
New +$3.17M
IOVA icon
74
Iovance Biotherapeutics
IOVA
$2.09B
$4.25M 0.3%
172,521
-2,479
-1% -$58.4K
MCRB icon
75
Seres Therapeutics
MCRB
$46.3M
$4.22M 0.3%
+30,328
New +$5.93M
1 2
3
4 5

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q3 2021 Portfolio in Review

As of Q3 2021, Ikarian Capital held 267 positions worth $1.42B, up 15% from $1.24B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Ikarian Capital deployed $291M of net new capital in Q3 2021, opening 57 new positions and adding to 30 existing holdings. Its largest new stake was Apellis Pharmaceuticals: 347,545 shares worth $11.5M.

By sector, the portfolio is most concentrated in Healthcare at 30% of assets, down from 44% a quarter earlier, followed by Consumer Staples and Technology.

On the sell side, the largest reduction was Biogen, an estimated $30.7M trimmed.

  • Ikarian Capital's largest Q3 2021 buy was Apellis Pharmaceuticals: 347,545 shares worth $11.5M.
  • Ikarian Capital added most to Inhibrx, Inc. Common Stock in Q3 2021, an estimated $8.57M increase.
  • Ikarian Capital's biggest Q3 2021 reduction was Biogen, cutting an estimated $30.7M.
  • Ikarian Capital fully exited Alector in Q3 2021, selling an estimated $14.1M.
  • Ikarian Capital's ten largest holdings make up 38% of its $1.42B portfolio in Q3 2021.
  • Ikarian Capital opened 57 new positions and closed 58 in Q3 2021.
  • Ikarian Capital's portfolio value rose 15% quarter-over-quarter to $1.42B.

Based on Ikarian Capital's 13F filing for Q3 2021, filed 15 Nov 2021.